Given the enhanced affinity of EV hybrids for DR5‐expressing cells, we studied their potential as drug delivery vehicles, specifically for targeting DR5‐expressing melanoma cells and delivery of cancer therapeutics. This evidence concerns the gene TNFRSF10B and melanoma.